Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
Rs 4417.67
Rs 397590.51Rs 4417.67
Rs 52984.58
60 tablet
Free AirMail shipping Hot
Rs 4712.11
Rs 282726.78Rs 4712.11
Rs 17656.62
30 tablet
Free AirMail shipping Hot
Rs 5006.39
Rs 150191.70Rs 5006.39
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
Rs 5301.24
Rs 477111.56Rs 5301.24
Rs 26477.56
60 tablet
Free AirMail shipping Hot
Rs 5448.42
Rs 326905.14Rs 5448.42
Rs 8820.95
30 tablet
Free AirMail shipping Hot
Rs 5595.43
Rs 167863.04Rs 5595.43
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
Rs 6332.07
Rs 569886.12Rs 6332.07
Rs 26477.56
60 tablet
Free AirMail shipping Hot
Rs 6479.25
Rs 388754.84Rs 6479.25
Rs 8820.95
30 tablet
Free AirMail shipping Hot
Rs 6626.26
Rs 198787.89Rs 6626.26
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.